Canada Saves CAD2bn Through Pricing Deal
But CGPA Warns Over Increasing Reliance On India And China For Supply
A five-year agreement between the Canadian Generic Pharmaceutical Association and the pan-Canadian Pharmaceutical Alliance has helped to save close to CAD2bn in prescription drug costs in Canada. However, the CGPA has expressed concern over price cuts that are forcing Canada increasingly to rely on supply from lower-cost jurisdictions such as China and India.
You may also be interested in...
Who’s Hired? Sandoz Names Post-Spinoff Chair
Sandoz has announced the appointment of a chairman-designate ahead of its planned separation from parent company Novartis this year. Meanwhile, Canadian industry association the CGPA has also named a new chair and vice-chair, while Formycon has appointed a new CFO.
Canada’s CGPA Welcomes Move Towards National Pharmacare
A renewed commitment from Canada’s government to a universal national pharmacare program, included in the latest federal budget, has been welcomed by the country’s generics and biosimilars industry.
Canadian Body Calls For Investment In Domestic Production
In a new “blueprint” document, the CGPA has called for investment in Canada’s domestic generic pharmaceutical infrastructure to bolster its manufacturing and supply capabilities, as well as urging an enhanced international role and a local stockpile of essential drugs.